Efficacy evaluation of medium-chain triglycerides supplementation on acute severe encephalopathy.

IF 3.6 4区医学 Q2 NEUROSCIENCES

Nutritional Neuroscience Pub Date : 2025-07-17 DOI:10.1080/1028415X.2025.2525513

Yanfang Zuo, Haotian Wu, Ping Liu, Zhihong Bian, Zhengqi Lu, Bingjun Zhang

{"title":"Efficacy evaluation of medium-chain triglycerides supplementation on acute severe encephalopathy.","authors":"Yanfang Zuo, Haotian Wu, Ping Liu, Zhihong Bian, Zhengqi Lu, Bingjun Zhang","doi":"10.1080/1028415X.2025.2525513","DOIUrl":null,"url":null,"abstract":"Background: This study assessed whether dietary medium-chain triglyceride (MCT) supplementation improves outcomes in acute severe encephalopathy patients within a Neurological Intensive Care Unit (NICU).Methods: A single-center, double-blind, randomized trial was conducted at The Third Affiliated Hospital of Sun Yat-sen University (May 2021 - August 2023). Forty-six patients were randomized to MCT supplementation (n = 23) or control (n = 23). Primary outcomes were 180-day poor neurologic outcome (modified Rankin Scale score >4) and all-cause mortality. Secondary outcomes included coma duration, mechanical ventilation duration, ICU length of stay, and hospital costs. Final follow-up was May 1, 2024.Results: At 180 days, poor neurologic outcome occurred in 26.1% (6/23) of the MCT group versus 56.5% (13/23) of controls (RR 0.27; 95% CI 0.08-0.94; P < 0.05). All-cause mortality was 13.0% (MCT) vs. 30.4% (control) (RR 0.43; 95% CI 0.13-1.46; P > 0.05). The MCT group showed significant improvements in all secondary outcomes: shorter coma duration (8.4 vs 13.2 days; P < 0.05), reduced mechanical ventilation (55.0 vs 154.9 h; P < 0.05), shorter ICU stay (13.4 vs 19.3 days; P < 0.05), and lower hospital costs (¥76,000 vs ¥100,200; P < 0.05).Conclusions: MCT supplementation significantly reduced poor neurologic outcomes at 180 days in acute severe encephalopathy patients. It also significantly shortened coma duration, mechanical ventilation time, ICU stay, and lowered hospital costs. Mortality reduction was not statistically significant.","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"1-8"},"PeriodicalIF":3.6000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutritional Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1028415X.2025.2525513","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study assessed whether dietary medium-chain triglyceride (MCT) supplementation improves outcomes in acute severe encephalopathy patients within a Neurological Intensive Care Unit (NICU).

Methods: A single-center, double-blind, randomized trial was conducted at The Third Affiliated Hospital of Sun Yat-sen University (May 2021 - August 2023). Forty-six patients were randomized to MCT supplementation (n = 23) or control (n = 23). Primary outcomes were 180-day poor neurologic outcome (modified Rankin Scale score >4) and all-cause mortality. Secondary outcomes included coma duration, mechanical ventilation duration, ICU length of stay, and hospital costs. Final follow-up was May 1, 2024.

Results: At 180 days, poor neurologic outcome occurred in 26.1% (6/23) of the MCT group versus 56.5% (13/23) of controls (RR 0.27; 95% CI 0.08-0.94; P < 0.05). All-cause mortality was 13.0% (MCT) vs. 30.4% (control) (RR 0.43; 95% CI 0.13-1.46; P > 0.05). The MCT group showed significant improvements in all secondary outcomes: shorter coma duration (8.4 vs 13.2 days; P < 0.05), reduced mechanical ventilation (55.0 vs 154.9 h; P < 0.05), shorter ICU stay (13.4 vs 19.3 days; P < 0.05), and lower hospital costs (¥76,000 vs ¥100,200; P < 0.05).

Conclusions: MCT supplementation significantly reduced poor neurologic outcomes at 180 days in acute severe encephalopathy patients. It also significantly shortened coma duration, mechanical ventilation time, ICU stay, and lowered hospital costs. Mortality reduction was not statistically significant.

查看原文本刊更多论文

补充中链甘油三酯治疗急性重症脑病的疗效评价。

背景：本研究评估了饮食中链甘油三酯（MCT）补充是否能改善神经重症监护病房（NICU）急性重症脑病患者的预后。方法：在中山大学第三附属医院进行单中心、双盲、随机试验（2021年5月- 2023年8月）。46例患者随机分为MCT补充组（n = 23）和对照组（n = 23）。主要结局为180天不良神经预后（改良Rankin量表评分bb0.4）和全因死亡率。次要结局包括昏迷时间、机械通气时间、ICU住院时间和住院费用。最后一次跟进是在2024年5月1日。结果：在180天，MCT组中有26.1%（6/23）的患者出现较差的神经系统预后，对照组为56.5% (13/23)(RR 0.27；95% ci 0.08-0.94；p p > 0.05)。MCT组在所有次要预后方面均有显著改善：昏迷时间缩短(8.4天vs 13.2天；结论：MCT补充可显著降低急性重症脑病患者180天的不良神经系统预后。同时显著缩短昏迷时间、机械通气时间、ICU住院时间，降低住院费用。死亡率降低无统计学意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutritional Neuroscience 医学-神经科学

CiteScore

8.50

自引率

2.80%

发文量

236

审稿时长

>12 weeks

期刊介绍： Nutritional Neuroscience is an international, interdisciplinary broad-based, online journal for reporting both basic and clinical research in the field of nutrition that relates to the central and peripheral nervous system. Studies may include the role of different components of normal diet (protein, carbohydrate, fat, moderate use of alcohol, etc.), dietary supplements (minerals, vitamins, hormones, herbs, etc.), and food additives (artificial flavours, colours, sweeteners, etc.) on neurochemistry, neurobiology, and behavioural biology of all vertebrate and invertebrate organisms. Ideally this journal will serve as a forum for neuroscientists, nutritionists, neurologists, psychiatrists, and those interested in preventive medicine.